Ironwood’s drug for IBS sufferers gets FDA approval

Fierce Pharma have reported that Ironwood Pharmaceuticals Inc.  and Forest Laboratories Inc.  won regulatory approval of their Linaclotide treatment for irritable bowel syndrome with constipation.

Linaclotide has shown in studies to help alleviate abdominal pain and symptoms of constipation. Ironwood has said that as many as 11 million Americans have irritable bowel syndrome with constipation, and for many it comes with a lot of pain. While Takeda Pharmaceutical is already in the market with its Amitiza, analysts say the fact

that the Ironwood drug may relieve pain will help it quickly outsell its competition.

Linaclotide was developed by Ironwood with New York-based Forest Labs, and the companies will co-promote the drug in the U.S. Ironwood licensed the drug in Europe to Barcelona, Spain- based Almirall SA (ALM), and to Tokyo-based Astellas Pharma Inc. (4503) for several Asian countries.

Looking for a new job in the pharmaceutical sector? Start by clicking here

Posted in: Industry News
CK Logo in place of featured image